EGFR and non-small cell lung carcinoma: In patients with EGFR-mutant NSCLC, ongoing clinical trials are investigating the efficacy of adjuvant osimertinib for patients with stage IA2–IA3 disease (phase 3 ADAURA2; NCT05120349) and whether extending therapy beyond three years to five years might be beneficial (phase 2 single-group TARGET; NCT05526755).